ACA
Avoro Capital Advisors Portfolio holdings
AUM
$5.71B
This Quarter Return
+3.66%
1 Year Return
+11.37%
3 Year Return
+255.37%
5 Year Return
+558.9%
10 Year Return
+18,722.72%
AUM
$7.51B
AUM Growth
+$7.51B
(-12%)
Cap. Flow
-$924M
Cap. Flow
% of AUM
-12.31%
Top 10 Holdings %
Top 10 Hldgs %
65.31%
Holding
49
New
3
Increased
11
Reduced
9
Closed
8
Top Buys
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$36M |
| 2 |
Ascendis Pharma
ASND
|
$31.4M |
| 3 |
Madrigal Pharmaceuticals
MDGL
|
$31.1M |
| 4 |
Avidity Biosciences
RNA
|
$27.8M |
| 5 |
Merus
MRUS
|
$27.6M |
Top Sells
| 1 |
Viking Therapeutics
VKTX
|
$294M |
| 2 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$229M |
| 3 |
Sarepta Therapeutics
SRPT
|
$212M |
| 4 |
SPDR S&P Biotech ETF
XBI
|
$117M |
| 5 |
MacroGenics
MGNX
|
$90.5M |
Sector Composition
| 1 | Healthcare | 96.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
United Therapeutics
UTHR
$13.8B
| $911M | 12.13% | 2,858,888 | – | – |
|
|
2
Madrigal Pharmaceuticals
MDGL
$9.76B
| $576M | 7.67% | 2,055,555 +111,111 | +6% | +$31.1M |
|
|
3
Ascendis Pharma
ASND
$11.8B
| $572M | 7.62% | 4,196,661 +229,995 | +6% | +$31.4M |
|
4
argenx
ARGX
$43.6B
| $533M | 7.09% | 1,238,467 | – | – |
|
|
5
Sarepta Therapeutics
SRPT
$1.78B
| $474M | 6.31% | 3,000,000 -1,344,444 | -31% | -$212M |
|
6
Krystal Biotech
KRYS
$4.27B
| $447M | 5.95% | 2,433,000 -122,555 | -5% | -$22.5M |
|
7
Apellis Pharmaceuticals
APLS
$3.48B
| $426M | 5.68% | 11,111,111 | – | – |
|
8
BioMarin Pharmaceuticals
BMRN
$11.2B
| $375M | 5% | 4,557,416 +192,416 | +4% | +$15.8M |
|
|
CERE
9
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $308M | 4.11% | 7,539,547 -16,008 | -0.2% | -$655K |
|
|
10
SPDR S&P Biotech ETF
XBI
$5.07B
| $281M | 3.75% | 3,035,000 -1,265,000 | -29% | -$117M |
|
11
Amicus Therapeutics
FOLD
$2.34B
| $272M | 3.62% | 27,400,000 | – | – |
|
|
12
Avidity Biosciences
RNA
$5.99B
| $266M | 3.54% | 6,505,000 +680,000 | +12% | +$27.8M |
|
13
Arrowhead Research
ARWR
$3.05B
| $231M | 3.08% | 8,888,888 +333,333 | +4% | +$8.66M |
|
14
Xenon Pharmaceuticals
XENE
$2.98B
| $221M | 2.94% | 5,666,666 | – | – |
|
|
ITCI
15
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $205M | 2.74% | 3,000,000 +525,000 | +21% | +$36M |
|
16
Vera Therapeutics
VERA
$1.38B
| $156M | 2.08% | 4,309,590 -955,410 | -18% | -$34.6M |
|
17
MoonLake Immunotherapeutics
MLTX
$3.54B
| $122M | 1.62% | 2,770,000 +190,000 | +7% | +$8.35M |
|
18
Kymera Therapeutics
KYMR
$2.95B
| $116M | 1.55% | 3,888,888 | – | – |
|
19
Alnylam Pharmaceuticals
ALNY
$58.5B
| $97.2M | 1.29% | 400,000 +100,000 | +33% | +$24.3M |
|
20
Iovance Biotherapeutics
IOVA
$807M
| $93.8M | 1.25% | 11,700,000 | – | – |
|
21
Soleno Therapeutics
SLNO
$3.6B
| $85.3M | 1.14% | 2,091,666 +466,666 | +29% | +$19M |
|
|
22
Merus
MRUS
$4.98B
| $80.2M | 1.07% | 1,355,000 +466,112 | +52% | +$27.6M |
|
23
Syndax Pharmaceuticals
SNDX
$1.41B
| $79.8M | 1.06% | 3,888,437 -333,785 | -8% | -$6.85M |
|
24
BioCryst Pharmaceuticals
BCRX
$1.74B
| $77.7M | 1.03% | 12,570,000 -480,000 | -4% | -$2.97M |
|
25
Kura Oncology
KURA
$686M
| $72.9M | 0.97% | 3,541,505 -308,495 | -8% | -$6.35M |
|